The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. Through its innovative business model, the MPP partners with governments, industry, civil society, international organisations, patient groups and other stakeholders to forecast, prioritise and license needed medicines. The organisation encourages generic manufacture and the development of new formulations through patent pooling.

To date, the MPP has signed agreements with eight patent holders for twelve HIV antiretrovirals, one hepatitis C direct-acting antiviral, one tuberculosis treatment and one HIV technology platform. Its generic partners have distributed 10.9 million patient-years of WHO-recommended HIV medicines to 125 countries, including 79 countries that were previously unable to benefit from generic competition (January 2012-June 2016). These numbers were calculated by the audit and advisory firm KPMG.

The MPP was founded and remains fully funded by UNITAID.